Drug intelligence / Profile preview

GAL-GNR-siBRAF

Development stage: Preclinical
Lead developer: Nanchang University
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**GAL-GNR-siBRAF** is an experimental, galactose-targeted gold-nanorod nanocarrier designed for hepatocellular carcinoma. It combines galactose for uptake through the asialoglycoprotein receptor on liver cancer cells, gold nanorods that generate heat following near-infrared irradiation, and a BRAF-targeting small interfering RNA that reduces expression of the B-Raf proto-oncogene. The reported preclinical system inhibited hepatoma-cell proliferation, migration, and invasion through BRAF knockdown, with near-infrared photothermal treatment providing a synergistic tumor-cell-killing effect. It is a research-stage nanomedicine rather than an approved therapeutic product.

Other names: GAL-GNR-siBRAFGAL-GNR-siBRAF nanosystem

Targets

ASGPR (Asialoglycoprotein Receptor 1)BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Beyond the preview

Go deeper on GAL-GNR-siBRAF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAL-GNR-siBRAF.

Explore the full profile